← Browse by Condition
Medical Condition
non hodgkin s lymphoma
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — non hodgkin s lymphoma Clinical Trials
How many clinical trials are currently recruiting for non hodgkin s lymphoma?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for non hodgkin s lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for non hodgkin s lymphoma?
non hodgkin s lymphoma research spans Phase 1 (6 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a non hodgkin s lymphoma clinical trial?
Eligibility criteria for non hodgkin s lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 6
Phase 2 5
Top Sponsors
3 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06208735 Phase 1
Recruiting
Enrollment
24 pts
Location
Canada
Sponsor
British Columbia Cancer Agency
NCT02259556 Phase 1, Phase 2
Recruiting
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT01890486
Recruiting
Enrollment
2,000 pts
Location
United States
Sponsor
Wake Forest University Health ...
NCT06014073 Phase 1, Phase 2
Recruiting
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT05806099 Phase 1, Phase 2
Recruiting
Enrollment
132 pts
Location
China
Sponsor
Beijing Mabworks Biotech Co., ...
NCT07882641 Phase 1, Phase 2
Recruiting
Enrollment
20 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT06343311 Phase 1, Phase 2
Recruiting
Enrollment
27 pts
Location
United States
Sponsor
Estrella Immunopharma, Inc.
Related Conditions
high grade b cell lymphoma (2) b cell leukemia (1) b cell acute lymphoblastic leukemia (1) diffuse large b cell lymphoma (1) primary mediastinal large b cell lymphoma pmbcl (1) mantle cell lymphoma (1) b cell lymphoma (1) hodgkin s lymphoma (1) acute myelogenous leukemia (1) acute lymphocytic leukemia (1) chronic myelogenous leukemia (1) hodgkin s disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology